NCPA releases latest survey on drug supply chain, staffing
The National Community Pharmacists Association has released the results of its latest survey of independent pharmacy owners/managers that seeks to provide context on supply chain concerns and labor challenges its members are facing.
Seventy-five percent of survey respondents say they are carrying Narcan naloxone nasal spray, which was recently approved as an over-the-counter opioid overdose treatment. This is slightly less than the 85% who said in September that they planned to carry the medication when possible. When asked whether they plan to carry the first daily oral contraceptive for sale in the U.S. without a prescription, 42% say they intend to when it’s available. Forty-four percent say they may but need more information.
Regarding GLP-1 agonists (a class of medications utilized in the treatment of Type 2 diabetes and obesity), 90% of respondents say they will stock and sell these products. Of them, nearly all (96%) report experiencing shortages or backorders of GLP-1 agonists and most are ordering the products upon paid claims (63%) rather than keeping a stock on hand (37%) due to their high price and reimbursement from pharmacy benefit managers that is often below the pharmacy’s cost to acquire the drug.
[Read more: Pharmacy orgs laud DIR fee and pharmacy access bill as vital for PBM reform]
“GLP-1s have been tremendously popular over the last couple of years and are an important, albeit expensive, option for many patients. But independent pharmacies are in the counterintuitive predicament of seeing top line revenues grow while the bottom line shrinks due to payments from PBM-insurers that are often significantly below the pharmacy’s cost to acquire the medication,” said Doug Hoey CEO of NCPA. “When added to the unsustainably low reimbursement pharmacies are seeing on other drugs, plus payment clawbacks, the steering of patients into PBM-insurer affiliated pharmacies and take-it-or-leave-it contracts, it’s a challenging time to own and operate a community pharmacy. Pharmacy’s reputation as the location with the most accessible health care provider in their communities is being threatened.”
Almost all respondents say they are experiencing additional supply issues, with 87% specifically reporting shortages of Adderall or generics, a slight decline from the September survey. Additionally, staffing in some independent pharmacies is continuing to be a challenge, with 67% saying it’s difficult to fill open staff positions. Pharmacy technicians continue to be in the highest demand (76%), followed by clerks/front-end staff (42%), pharmacists (36%) and delivery drivers (17%).
[Read more: The Future of Pharmacy Care Coalition applauds intro of Senate legislation]
This NCPA survey was conducted from Feb. 2-12, 2024. It was sent to approximately 10,000 independent pharmacy owners and managers, with 385 responding.